investor.aradigm.com
Investor Relations | Aradigm CorporationThe Investor Relations website contains information about Aradigm Corporation's business for stockholders, potential investors, and financial analysts.
http://investor.aradigm.com/
The Investor Relations website contains information about Aradigm Corporation's business for stockholders, potential investors, and financial analysts.
http://investor.aradigm.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.3 seconds
16x16
32x32
64x64
128x128
160x160
192x192
256x256
PAGES IN
THIS WEBSITE
11
SSL
EXTERNAL LINKS
10
SITE IP
23.55.218.214
LOAD TIME
0.273 sec
SCORE
6.2
Investor Relations | Aradigm Corporation | investor.aradigm.com Reviews
https://investor.aradigm.com
The Investor Relations website contains information about Aradigm Corporation's business for stockholders, potential investors, and financial analysts.
investor.aradigm.com
Aradigm Corporation - Printed Materials
http://investor.aradigm.com/InvestorKit.cfm
No documents are currently available to order by mail.
Aradigm Corporation - Financial Information
http://investor.aradigm.com/financials.cfm
Here you will find a summary of Aradigm Corporation's latest financial information. Latest Earnings Release and 10-Q. Second Quarter Financial Results. Aug 11, 2016. May 10, 2016. Aug 16, 2016. May 11, 2016. May 9, 2016. Mar 30, 2016. May 16, 2016. Proxy Statement (PRE 14A). May 6, 2016. Add file to Briefcase. Data is currently unavailable. Market Cap. (Mil). Share Related information provided by MorningStar, Inc. Data as of Aug 27, 2016.
Aradigm Corporation - Corporate Governance
http://investor.aradigm.com/governance.cfm
Nominating and Corporate Governance Committee. Add file to Briefcase.
Aradigm Corporation - Events & Presentations
http://investor.aradigm.com/events.cfm
Currently, there are no events scheduled. Please click here. To be notified of all upcoming events. ORBIT-3 and ORBIT-4: Design of a Phase 3 Program to Investigate Safety and Efficacy of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas Aeruginosa (PA). Liposome-Ciprofloxacin inhibits Mycobacterium avium subsp hominissuis (MAH) microaggregate formation in dose and time-related manner. Add file to Briefcase.
Aradigm Corporation - Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2015 International Conference
http://investor.aradigm.com/releasedetail.cfm?releaseid=912485
Laquo; Previous Release. Next Release ». Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2015 International Conference. BUSINESS WIRE)- Scientists from the. Was reduced by 79% and 77% by Lipoquin and Pulmaquin, respectively (p < 0.05) compared to saline controls. In contrast, unencapsulated ciprofloxacin had no effect. Professor of Biomedical Sciences at OSU. 1:30 pm-3:30 pm on Wednesday. Abstract...
TOTAL PAGES IN THIS WEBSITE
11
Aradigm-Careers Culture, Learning Program
http://www.aradigm.com/careers_culture.html
Why We Work Here. We Are Goal-Driven and Performance-Focused and Our Patients' Well-Being is Our Highest Priority. Bull; At Aradigm, we’re goal-driven and performance-focused. We’re highly team-oriented—while also encouraging individual achievement and recognition. Bull; The patients’ well-being is our highest priority. We strive to perform quality work that rapidly leads to products that benefit patients.
Aradigm-Bronchiectasis Clinical Trials | Smoking Cessation
http://www.aradigm.com/products_pipeline.html
Inhalation Drug Treatments to Prevent and Treat Severe Respiratory Diseases. Below is a list of proprietary programs and their respective stages of development. In addition to these current programs, Aradigm continues to apply its expertise and intellectual property to other potential therapeutic applications that may benefit from the Company's novel formulations and drug delivery technology. Biodefense (inhalational tularemia, pneumonic plague, Q-fever).
Aradigm-Biodefense and Cystic Fibrosis Inhaled Antibiotics
http://www.aradigm.com/about.html
Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease. Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team for example, pioneered the AERx.
Aradigm-Site Map
http://www.aradigm.com/sitemap.html
Bull; About Aradigm. Bull; Business Overview. Bull; Product Pipeline. Bull; Other Applications. Bull; Scientific Publications. Bull; AERx Inhalation Technology Platform. Bull; Liposomal Formulations. Bull; Intellectual Property. Bull; Press Releases. Bull; Reports and Filings. Bull; Earnings Estimates. Bull; Analyst Coverage. Bull; Stock Chart. Bull; Non-GAAP Financial Measures. Bull; Info Request. Bull; Corporate Presentations. Bull; Open Positions. Bull; Why We Work Here. Bull; Press Releases.
Aradigm-Non-Cystic Fibrosis Bronchiectasis | Clinical Trial Information
http://www.aradigm.com/clin_patients.html
Clinical Trial Information for Patients. Currently Active Clinical Trials. Trial is a Phase III international research study to test the safety and effectiveness of the investigational drug known as. Compared to placebo in. Non-cystic fibrosis bronchiectasis patients. Similar to the ORBIT-3. Study, the ORBIT-4. Trial is a Phase III international research study to test the safety and effectiveness of the investigational drug known as. Compared to placebo in. Non-cystic fibrosis bronchiectasis patients.
Aradigm-News & Events | Non-Tb Mycobacteria Treatments | Orbit Clinical Program
http://www.aradigm.com/news-events.html
Aradigm Corporation Prices Private Placement of Senior Notes. Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency. Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results. Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO and Investor Conference 2016 on February 8. Aradigm to Host Corporate Update Conference Call on January 6. Aradigm Announces Third Quarter 2015 Financial Results. May 11, 2015. Aradigm to Host Key Opinion Le...
TOTAL LINKS TO THIS WEBSITE
10
Investor Relations | Anthera Pharmaceuticals, Inc.
Skip to main navigation. Phone: 1.510.856.5600. We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Delayed at least 20 minutes. March 12, 2018. Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura. March 7, 2018. Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference. View all press releases. March 12, 2018. March 12, 2018. View all events and presentations.
Investor Overview | Alpha and Omega Semiconductor
Skip to main navigation. 31616;体中文. Powering a Greener Future ™. Investor Information and Tools. Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer and global supplier of a broad range of power semiconductor products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of adva...
Investor Relations - A.O. Smith Corporation
Looking for a water heater? July 23, 2015. A O Smith reports record earnings on strong global sales growth; raises full year EPS guidance over 10 percent. July 1, 2015. A O Smith to hold second quarter conference call on July 23. View all financial releases ». August 13, 2015. 2015 Summer Investor Presentation. July 23, 2015 at 10:00 AM ET. Second Quarter 2015 Earnings Call. May 27, 2015. Spring 2015 Investor Presentation. View all events and presentations ». A O Smith Water Heaters: See How They're Made.
AppliedMicro - Powering Your Cloud Network - Investor Relations - Investor Relations
Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. 160;at 10:25 am ET. Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. Wednesday, August 12, 2015 . 10:25 am ET . Click here for webcast. Click here to add this event to your calendar. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference. 160;at 11:00 am ET. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference.
Investor Relations - Aquinox Pharmaceuticals, Inc
Activate excellence. Activate innovation. Activate success. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Aquinox Pharmaceutical Inc's financial performance into perspective. Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC and Reports Second Quarter 2015 Financial Results. View all press releases ». 8/13/15 at 3:00 PM ET.
Investor Relations | Aradigm Corporation
Skip to main navigation. Mar 29, 2018. Transfer Agent and Registrar. Communications concerning stock transfer requirements, lost certificates and change of address should be directed to:. Shareholder correspondence should be mailed to:. College Station, TX 77842-3170. Overnight correspondence should be sent to:. 211 Quality Circle, Suite 210. College Station, TX 77845. Https:/ www-us.computershare.com/investor/Contact. Mar 23, 2018. Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results.
Arbutus Biopharma - Investor Relations
The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».
Arch Coal, Inc. | Investors: Investor Relations Home
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Arch Coal's performance into perspective. Arch Coal is listed on the New York Stock Exchange (NYSE: ACI) and maintains its corporate headquarters in St. Louis, Mo. Arch Coal, Inc. Reports Second Quarter 2015 Results. Supplemental Historical Information Regional Realization and Cost Analysis. 2014 Annual Report Narrative. Or www.amstock.com.
ARIAD Pharmaceuticals, Inc: Investor home
Our Name and Logo. Our Vision, Mission and Values. Our Vision, Mission and Values. Key to long-term value: discipline, execution and consistent communication. ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer an...
Investors — Investor Information - ARI
ARI - We Create Connections. ARI has helped us support the 9 manufacturer brands we sell which has been. Essential to our growth. Our OEM part sales are up 265%. From last year.". Mdash; Powersports Dealer. Services for the Powersports industry. Up-to-date information from all of my manufacturers is critical to my business. Working with ARI saves us more than $450 per week. In outsourcing fees while growing my parts business by 125%. Mdash; OPE Dealer. Services for the Outdoor Power Equipment industry.
AP investor
LHV Maailma Aktsiad Fond A. LHV Maailma Aktsiad Fond B. Nordea Pensionifond Aktsiad 100. Danske Pension 100 Pluss. Mandatum Life Indonesia Index. Mandatum Life Australia Index. Mandatum Life Russia Index. Mandatum Life Brazil Index. Mandatum Life India Index. Hetkel tehinguid sooritatud pole. Nordea Pensionifond A Pluss. NASDAQ OMX Tallinna, Riia ja Vilniuse börsiinfo 15 minutilise viivisega. Info uuendamiseks kasuta "uuenda/refresh" nuppu lehe pealkirja vasakus servas.
